Sorafenib: all 509 studies that test it
Page 5 of 6. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.
- Sequential Study to Treat Renal Cell CarcinomaCompletedNCT00732914Phase 3
- Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform NeurofibromasCompletedNCT00727233Phase 1
- Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerStatus unknownNCT00722969Phase 2
- A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular CarcinomaCompletedNCT00712855Phase 1
- Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)CompletedNCT00712790Phase 1/2
- Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid TumorsCompletedNCT00703638Phase 1
- Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)CompletedNCT00703365Phase 2
- Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate CancerWithdrawnNCT00694291Phase 2
- Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and LeukemiaCompletedNCT00665990Phase 1
- Sorafenib Gastric Cancer Asian Phase I StudyCompletedNCT00663741Phase 1
- BAY43-9006 Phase II Study for Renal Cell CarcinomaCompletedNCT00661375Phase 2
- Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to GleevecCompletedNCT00661180Phase 2
- Extension Program for Bay 43-9006CompletedNCT00657254Phase 2
- Phase I Study of Vorinostat and Sorafenib in Advanced CancerCompletedNCT00635791Phase 1
- Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)WithdrawnNCT00627835Phase 1
- Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic MelanomaCompletedNCT00623402Phase 2
- Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.TerminatedNCT00622479Phase 1
- Study of Sorafenib and Docetaxel in Metastatic Prostate CancerCompletedNCT00619996Phase 2
- Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC)CompletedNCT00619541Phase 2
- TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)TerminatedNCT00618384Phase 2
- Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid TumorsCompletedNCT00613145Phase 1
- A Study of Radiation With Sorafenib in Advanced CancerCompletedNCT00610246Phase 1
- Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the BoneCompletedNCT00609934Phase 1/2
- A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast CancerTerminatedNCT00607438Phase 2
- MRI Study of BAY 43-9006 in Metastatic Renal Cell CarcinomaCompletedNCT00606866Phase 3
- Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid TumorsCompletedNCT00606125Phase 1
- Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250CompletedNCT00602862Not applicable
- Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric CancerTerminatedNCT00595985Phase 2
- Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid TumorsCompletedNCT00572078Phase 1
- Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or LegCompletedNCT00565968Phase 1
- Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and DoxorubicinCompletedNCT00562913Phase 1
- Sorafenib/Docetaxel Dose Escalation TrialCompletedNCT00562523Phase 1
- Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast CancerCompletedNCT00548899Phase 2
- Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung CancerWithdrawnNCT00547443Phase 1/2
- Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative IntentCompletedNCT00544609Phase 1
- Bevacizumab in Multiple Phase I CombinationsCompletedNCT00543504Phase 1
- Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung CancerTerminatedNCT00543335Phase 1
- Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue SarcomaStatus unknownNCT00541840Phase 1/2
- Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerStatus unknownNCT00541021Phase 3
- Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant MelanomaStatus unknownNCT00538005Phase 1/2
- BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00533585Phase 1
- Sorafenib in Resected Non-small Cell Lung CarcinomaTerminatedNCT00532025Phase 2
- A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical CancerCompletedNCT00510250Phase 1/2
- Phase 1 Study With Sorafenib and SirolimusCompletedNCT00509613Phase 1
- Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast CancerStatus unknownNCT00499525Phase 2
- Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant MelanomaCompletedNCT00498836Phase 2
- Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCCCompletedNCT00496301Phase 2
- Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell CancerActive, not recruitingNCT00494182Phase 2
- An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell CarcinomaCompletedNCT00492986Phase 3
- Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III MelanomaStatus unknownNCT00492505Phase 2
- Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney CancerCompletedNCT00492258Phase 3
- Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)CompletedNCT00490685Phase 2
- A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic MelanomaCompletedNCT00483301Phase 2
- Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney RemovalCompletedNCT00480389Phase 2
- Sorafenib With TACE to Treat Hepatocellular CarcinomaCompletedNCT00478374Phase 1
- Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)CompletedNCT00478114Phase 3
- Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus SorafenibTerminatedNCT00473486Phase 1/2
- Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung CancerCompletedNCT00466232Phase 1
- Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)CompletedNCT00464919Phase 2
- Sorafenib in BAC or Never-Smokers With Lung AdenocarcinomaCompletedNCT00456716Phase 2
- Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)CompletedNCT00452218Phase 1
- Drug Interaction Study of Sorafenib and Rapamycin in Advanced MalignanciesCompletedNCT00449280Phase 1
- Safety and Toxicity Study of Sorafenib in Patients With Kidney CancerCompletedNCT00445042Phase 2
- Sorafenib in Treating Patients With Advanced Solid TumorsTerminatedNCT00436579Phase 1
- A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate CancerCompletedNCT00430235Phase 2
- Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic MelanomaCompletedNCT00418496Phase 1
- BAY-43-9006 in Advanced, Metastatic Soft Tissue SarcomasCompletedNCT00406601Phase 2
- Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney CancerCompletedNCT00405366Early Phase 1
- Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic CancerCompletedNCT00405210Phase 1
- Phase I Study of Perifosine + Sorafenib for Patients With Advanced CancersCompletedNCT00398814Phase 1
- Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell CarcinomaCompletedNCT00389285Phase 1/2
- Sorafenib and RAD001 Renal Cell CarcinomaCompletedNCT00384969Phase 1
- Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic CancerCompletedNCT00375310Phase 1
- Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AMLCompletedNCT00373373Phase 2
- Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable MelanomaCompletedNCT00349206Phase 1
- Sorafenib and Bortezomib in Treating Patients With Advanced CancerCompletedNCT00303797Phase 1
- Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the BrainCompletedNCT00301847Phase 2
- BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's SarcomaTerminatedNCT00287495Phase 1
- Sorafenib in Treating Patients With Recurrent Non-Hodgkin's LymphomaCompletedNCT00278382Phase 2
- Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer PatientsCompletedNCT00259129Phase 1
- Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00255658Phase 1
- Sorafenib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00253578Phase 2
- Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced CancerCompletedNCT00244972Phase 1
- S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or CholangiocarcinomaCompletedNCT00238212Phase 2
- Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00217646Phase 1
- Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00199160Phase 2
- Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal CancerCompletedNCT00134069Phase 1
- Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00131989Phase 1
- Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00126620Phase 1
- 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00121264Phase 1
- Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006CompletedNCT00119639Phase 1
- Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00119249Phase 2
- Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionCompletedNCT00118170Phase 1
- Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell CarcinomaCompletedNCT00111020Phase 3
- Research Study for Patients With Metastatic Renal Cell CarcinomaTerminatedNCT00110344Phase 2
- Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.CompletedNCT00107432Phase 2
- Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00101114Phase 2
- Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney CancerTerminatedNCT00098618Phase 2
- Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00098540Phase 2
- S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00096512Phase 2